About Transcription factor E2F2
Transcription factor E2F2 (E2F2) is a protein
from Homo sapiens identified by UniProt accession
Q14209, 437 residues long.
MolForge cross-references it against 0 known binders and
263 disease associations.
Target properties
| Protein name | Transcription factor E2F2 |
| UniProt accession | Q14209 |
| Gene | E2F2 |
| Organism | Homo sapiens |
| Length | 437 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (263)
Diseases linked to this target (Open Targets).
- mean corpuscular volume · score 0.46
- Red cell distribution width · score 0.45
- eosinophil count · score 0.45
- mean corpuscular hemoglobin · score 0.44
- leukocyte count · score 0.42
- mean corpuscular hemoglobin concentration · score 0.42
- erythrocyte count · score 0.40
- reticulocyte count · score 0.40
- neutrophil count · score 0.40
- neurodegenerative disease · score 0.37
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q14209-F1 | alphafold | PREDICTED | 63.13 | — |
Amino-acid sequence (437 residues)
MLQGPRALAS AAGQTPKVVP AMSPTELWPS GLSSPQLCPA TATYYTPLYP QTAPPAAAPG TCLDATPHGP EGQVVRCLPA GRLPAKRKLD LEGIGRPVVP EFPTPKGKCI RVDGLPSPKT PKSPGEKTRY DTSLGLLTKK FIYLLSESED GVLDLNWAAE VLDVQKRRIY DITNVLEGIQ LIRKKAKNNI QWVGRGMFED PTRPGKQQQL GQELKELMNT EQALDQLIQS CSLSFKHLTE DKANKRLAYV TYQDIRAVGN FKEQTVIAVK APPQTRLEVP DRTEDNLQIY LKSTQGPIEV YLCPEEVQEP DSPSEEPLPS TSTLCPSPDS AQPSSSTDPS IMEPTASSVP APAPTPQQAP PPPSLVPLEA TDSLLELPHP LLQQTEDQFL SPTLACSSPL ISFSPSLDQD DYLWGLEAGE GISDLFDSYD LGDLLIN
Explore Transcription factor E2F2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets